Global Autoimmune Disease Diagnostics Market Growth, Trends and Forecasts (2017 - 2022)

The global autoimmune disease diagnostics market is expected to reach USD18.2 billion by 2020 from USD12.8 billion in 2014. During this period, the CAGR is expected to be 6.04%

Autoimmune diseases are a group of diseases characterized by inflammatory reactions caused by immune responses mistakenly generated against body tissues. Rheumatoid arthritis is an example of an autoimmune disease that affects women more than men. Recent discoveries in diagnostic techniques in autoimmune disease are driving the market. Although the disease is rare, continuous innovations and developments in the diagnostic provide market opportunities for industry participants.

Global Autoimmune Disease Diagnostics Market- Market Dynamics

The report details several driving and restraining factors for the autoimmune disease diagnostics market. Some of these are listed below.


Growing public awareness for autoimmune disorders

Improved laboratory techniques and automation

Increase in partnerships between physicians and clinical laboratories

Rising incidences of the disease like Rheumatoid arthritis, Graves and Hashimoto's Thyroid Disease, lupus and type 1diabetes


Slow turnaround time for autoimmune disease diagnostic test results and high frequency of false positive results are the factors which are slowing down the market.

Despite the lower incidence and prevalence rate, the market size of Southern Asia is sizable because of its large population. Western countries show increasing incidence of autoimmune disorder because of the changing lifestyle, hygiene, and unhealthy eating. Revenue growth is primarily driven in the United States market where the incidence of gastrointestinal autoimmune conditions primarily celiac disease is on the rise. In the US alone, 8% of the population suffers from autoimmune diseases, 78% of which are women.

Global autoimmune disease diagnostics market is segmented based on type (localized autoimmune disease diagnostic and systemic autoimmune disease diagnostic ), products( drugs, therapeutic and monitoring equipment, diagnostic equipment), service market( consultation and diagnosis, therapy & monitoring, drug development and discovery), technology( bridge therapy, DMARD, topical therapy, phototherapy, helminthic therapy, recombinant technology)and geography( US, Europe, Asia-Pacific, RoW).

Some of the key players in the market are:


F.Hoffmann-La Roche

Novartis AG

Pfizer Inc.


What the Report Offers

Market definition for global autoimmune disease diagnostics along with identification of key drivers and restraints for the market.

Market analysis for the autoimmune disease diagnostic, with region-specific assessments and competition analysis on a global and regional scale.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their share of markets.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.

Reasons for Buying this Report

To gain an exhaustive understanding of the worldwide market for global autoimmune disease diagnostics.

The report will be of assistance in providing a comprehensive analysis of the major trends, innovations and associated prospects for market growth over the coming half a decade.

An ideal opportunity for industry consultants and other interested and allied parties to gain a critical insight into the factors driving and restraining the market, in addition to opportunities, offered.

Wide-ranging information provided about the leading market players and the major strategies adopted by them.


1.1 Study deliverables

1.2 Market Definition

1.3 Sizing Units

1.4 Base Currency

1.5 Review and forecast period years

1.6 General Study Assumptions


2.1 Introduction

2.2 Analysis Methodology

2.3 Econometric forecast models

2.4 Research Assumptions




5.1 Current market scenario

5.2 Technology Overview

5.3 Porters Five Force Analysis

5.3.1 Bargaining Power of suppliers

5.3.2 Bargaining power of buyers

5.3.3 Degree of competition

5.3.4 Threat of substitution

5.3.5 Threat of new entrants


6.1 Market Drivers

6.1.1 Growing Public awareness of autoimmune disease

6.1.2 Improved Laboratory Automation

6.1.3 Partnerships with Physicians and Clinical Laboratories

6.1.4 Technological advancements

6.1.5 Expansion in Coverage Allowed by Patient Protection and Affordable Care Act

6.2 Market Restraints

6.2.1 Slow turnaround Time for Autoimmune Disease Diagnostic Test Results

6.2.2 High frequency of false positive result

6.3 Market opportunities

6.3.1 EU funded research projects like PRECISESADS

6.3.2 AARDA initiatives

6.3.3 High prevalence rate of autoimmune disease

6.4 Key Challenges

6.4.1 Shortage of skilled personnel

7. Global Autoimmune Disease Diagnostic market segmentation

7.1 By disease type

7.1.1 Systemic autoimmune disease Rheumatoid Arthritis Psoriasis Systemic Lupus Erythematosus (SLE) Multiple Sclerosis Others

7.1.2 Localized autoimmune disease Inflammatory Bowel disease Type 1 Diabetes Thyroid Others

7.2 By Diagnostics

7.2.1 Immunofluorescence assays (IFA)

7.2.2 Enzyme-linked Immunosorbent Assay (ELISA)

7.2.3 Western Blotting

7.2.4 Dot blot

7.2.5 Line blot

7.2.6 Multiplex immunoassay

7.2.7 Agglutination

7.2.8 Double immune diffusion

7.2.9 Counterimmunoelectrophoresis

8. Global Autoimmune Disease Diagnostic market by Geography - Regional shares and forecast

8.1 North America

8.1.1 United States

8.1.2 Canada

8.1.3 Mexico

8.2 Europe

8.2.1 Germany

8.2.2 UK

8.2.3 France

8.2.4 Italy

8.2.5 Spain & Portugal

8.2.6 Scandinavia

8.2.7 Benelux

8.2.8 Rest of Europe

8.3 Asia-Pacific

8.3.1 China

8.3.2 Japan

8.3.3 India

8.3.4 Australia & New Zealand

8.3.5 South Korea

8.3.6 Rest of Asia-Pacific

8.4 Middle East and Africa

8.4.1 GCC

8.4.2 South Africa

8.4.3 Rest of the Middle East and Africa

8.5 Latin America

8.5.1 Brazil

8.5.2 Argentina

8.5.3 Rest of Latin America

9. Competitive Landscape

9.1 Merger and Acquisition Analysis

9.2 New Product Launches

9.3 Agreements, Collaborations & Partnerships

10. Company Profiles

10.1 F.Hoffmann-La Roche

10.2 Novartis AG

10.3 Sanofi-aventis

10.4 AstraZeneca

10.5 Lycera

10.6 Pfizer Inc.

10.7 Celgene Corporation

10.8 Bristol-Myers Squibb

10.9 Eli Lilly

11. Analyst Outlook for Investment Opportunities

12. Future Outlook of the Market

Content are not available

Choose License Type